We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Pathogens Help Diagnose Fatty Liver Disease

By LabMedica International staff writers
Posted on 25 May 2017
Nonalcoholic fatty liver disease is a condition characterized by a buildup of fat in the liver and the condition is often not detected until it is well advanced, and a definitive diagnosis requires an invasive biopsy of the liver.

The presence of advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is the most important predictor of liver mortality, but there are limited data on the diagnostic accuracy of gut microbiota-derived signature for predicting the presence of advanced fibrosis.

Scientists at the University of California-San Diego examined 86 patients with NAFLD diagnosed by biopsy, including 72 with mild or moderate disease and 14 with advanced disease. More...
They characterized the gut microbiome compositions using whole-genome shotgun sequencing of DNA extracted from stool samples.

This process identified 37 species of bacteria that differentiated advanced NAFLD from the mild or moderate stage with 93.6% accuracy. The scientists then validated the finding in a second group of 16 patients with advanced NAFLD and 33 healthy volunteers who acted as controls. This time, they found that by testing the relative abundance of nine species of bacteria, seven of which were in the 37 identified previously, they could differentiate the NAFLD patients from the controls with 88% accuracy.

Karen E. Nelson, PhD, president of the J. Craig Venter Institute and a senior author of the study, said, “We believe our study sets the stage for a potential stool-based test to detect advanced liver fibrosis based simply on microbial patterns, or at least help us minimize the number of patients who have to undergo liver biopsies.” The study was published on May 2, 2017, in the journal Cell Metabolism.


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.